```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:X

LOGINID:ssptasjl1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  MAR 15  WPIDS/WPIX enhanced with new FRAGHITSTR display format
 NEWS  3  MAR 16  CASREACT coverage extended
 NEWS  4  MAR 20  MARPAT now updated daily
 NEWS  5  MAR 22  LWPI reloaded
 NEWS  6  MAR 30  RDISCLOSURE reloaded with enhancements
 NEWS  7  APR 02  JICST-EPLUS removed from database clusters and STN
 NEWS  8  APR 30  GENBANK reloaded and enhanced with Genome Project ID field
 NEWS  9  APR 30  CHEMCATS enhanced with 1.2 million new records
 NEWS 10  APR 30  CA/CAplus enhanced with 1870-1889 U.S. patent records
 NEWS 11  APR 30  INPADOC replaced by INPADOCDB on STN
 NEWS 12  MAY 01  New CAS web site launched
 NEWS 13  MAY 08  CA/CAplus Indian patent publication number format defined
 NEWS 14  MAY 14  RDISCLOSURE on STN Easy enhanced with new search and display
                  fields
 NEWS 15  MAY 21  BIOSIS reloaded and enhanced with archival data
 NEWS 16  MAY 21  TOXCENTER enhanced with BIOSIS reload
 NEWS 17  MAY 21  CA/CAplus enhanced with additional kind codes for German
                  patents
 NEWS 18  MAY 22  CA/CAplus enhanced with IPC reclassification in Japanese
                  patents
 NEWS 19  JUN 27  CA/CAplus enhanced with pre-1967 CAS Registry Numbers
 NEWS 20  JUN 29  STN Viewer now available
 NEWS 21  JUN 29  STN Express, Version 8.2, now available
 NEWS 22  JUL 02  LEMBASE coverage updated
 NEWS 23  JUL 02  LMEDLINE coverage updated
 NEWS 24  JUL 02  SCISEARCH enhanced with complete author names
 NEWS 25  JUL 02  CHEMCATS accession numbers revised
 NEWS 26  JUL 02  CA/CAplus enhanced with utility model patents from China

 NEWS EXPRESS  29 JUNE 2007:  CURRENT WINDOWS VERSION IS V8.2,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *
```

```
FILE 'HOME' ENTERED AT 09:49:14 ON 10 JUL 2007

=> fil reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 09:49:25 ON 10 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    9 JUL 2007  HIGHEST RN 941818-42-4
DICTIONARY FILE UPDATES:   9 JUL 2007  HIGHEST RN 941818-42-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10551933-A.str

L1      STRUCTURE UPLOADED

=>
Uploading C:\Program Files\Stnexp\Queries\10551933-B.str

L2      STRUCTURE UPLOADED

=>
Uploading C:\Program Files\Stnexp\Queries\10551933-C.str

L3      STRUCTURE UPLOADED

=> s l1 sss full
FULL SEARCH INITIATED 09:50:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    45490 TO ITERATE

100.0% PROCESSED    45490 ITERATIONS                          284 ANSWERS
SEARCH TIME: 00.00.01

L4          284 SEA SSS FUL L1

=> s l2 sss full
FULL SEARCH INITIATED 09:50:26 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    45490 TO ITERATE

100.0% PROCESSED    45490 ITERATIONS                            2 ANSWERS
SEARCH TIME: 00.00.01
```

L5 2 SEA SSS FUL L2

=> s l3 sss full
FULL SEARCH INITIATED 09:50:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 686078 TO ITERATE

100.0% PROCESSED 686078 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.04

L6 5 SEA SSS FUL L3

=> s l4 or l5 or l6
L7 291 L4 OR L5 OR L6

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1
G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> d l2
L2 HAS NO ANSWERS
L2 STR



G1
G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> d l3
L3 HAS NO ANSWERS
L3 STR



G1

G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	516.30	516.51

FILE 'CAPLUS' ENTERED AT 09:51:15 ON 10 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 10 Jul 2007 VOL 147 ISS 3
FILE LAST UPDATED: 9 Jul 2007 (20070709/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

(FILE 'HOME' ENTERED AT 09:49:14 ON 10 JUL 2007)

FILE 'REGISTRY' ENTERED AT 09:49:25 ON 10 JUL 2007
L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 STRUCTURE UPLOADED

```
L4          284 S L1 SSS FULL
L5            2 S L2 SSS FULL
L6            5 S L3 SSS FULL
L7          291 S L4 OR L5 OR L6

     FILE 'CAPLUS' ENTERED AT 09:51:15 ON 10 JUL 2007

=> s l7
L8            9 L7

=> d l8 tot bib abs hitstr
```

L8 1 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:461153 CAPLUS

DN 143:125827

TI Novel ketal ligands for the glucocorticoid receptor: in vitro and in vivo activity

AU Smith, Cameron J.; Ali, Amjad; Balkovec, James M.; Graham, Donald W.; Hammond, Milton L.; Patel, Gool F.; Rouen, Gregory P.; Smith, Scott K.; Tata, James R.; Einstein, Monica; Ge, Lan; Harris, Georgianna S.; Kelly, Theresa M.; Mazur, Paul; Thompson, Chris M.; Wang, Chuanlin F.; Williamson, Joanne M.; Miller, Douglas K.; Pandit, Shilpa; Santoro, Joseph C.; Sitlani, Ayesha; Yamin, Ting-ting D.; O'Neill, Edward A.; Zaller, Dennis M.; Carballo-Jane, Ester; Forrest, Michael J.; Luell, Silvi

CS Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ, 07065, USA

SO Bioorganic & Medicinal Chemistry Letters (2005), 15(11), 2926-2931
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier B.V.

DT Journal

LA English

OS CASREACT 143:125827

GI



I

AB A novel series of selective ligands for the human glucocorticoid receptor is described. Structure-activity studies focused on variation of B-ring size, ketal ring size, and ketal substitution. These analogs were found to be potent and selective ligands for GR and have partial agonist profiles in functional assays for transactivation (TAT, GS) and transrepression (IL-6). Of these compds., three were evaluated further in a mouse LPS-induced TNF-α secretion model. Compound (I) had an ED50 of 14.1 mg/kg compared with 0.5 mg/kg for prednisolone in the same assay.

IT 786708-06-3
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(novel ketal ligands for glucocorticoid receptor and in vitro and in vivo activity)

RN 786708-06-3 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 4',5'-diethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 786708-45-0P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(novel ketal ligands for glucocorticoid receptor and in vitro and in vivo activity)
RN 786708-45-0 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 4',5'-diethyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, stereoisomer (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 786708-33-6
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel ketal ligands for glucocorticoid receptor and in vitro and in vivo activity)
RN 786708-33-6 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,6'-trimethyl-, (4'S,4aS,6'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 614762-99-1P 786707-55-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(novel ketal ligands for glucocorticoid receptor and in vitro and in vivo activity)
RN 614762-99-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-55-9 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 786707-70-8
RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(novel ketal ligands for glucocorticoid receptor and in vitro and in vivo activity)
RN 786707-70-8 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 786707-65-1P 786707-67-3P 786707-68-4P
858371-49-0P 858371-51-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(novel ketal ligands for glucocorticoid receptor and in vitro and in vivo activity)

RN 786707-65-1 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-67-3 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-dipropyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-68-4 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-dibutyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 858371-49-0 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-di-2-propenyl-, (4'R,4aS,5'R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 858371-51-4 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4',5'-di-2-propenyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 786707-63-9 786708-10-9 786708-11-0
786708-14-3 786708-15-4 786708-16-5
786708-17-6 786708-18-7 786708-19-8
786708-20-1 786708-21-2 786708-34-7
786708-36-9 787619-93-6 787620-00-2
787620-02-4 787620-09-1 787620-10-4
858371-54-7 858371-55-8 858371-57-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel ketal ligands for glucocorticoid receptor and in vitro and in vivo activity)

RN 786707-63-9 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4',4a,5'-trimethyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-10-9 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4',5'-diphenyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-11-0 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',5'-bis(methoxymethyl)-4a-methyl-, (4'R,4aS,5'R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-14-3 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'R,4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-15-4 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'S,4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-16-5 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'R,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-17-6 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'S,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-18-7 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4'-phenyl-, (2'S,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-19-8 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4'-phenyl-, (2'R,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-20-1 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4'-phenyl-, (2'R,4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-21-2 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4'-phenyl-, (2'S,4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-34-7 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a,5',5'-trimethyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-36-9 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4',4a,6'-tetramethyl-, (2'S,4aS,6'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787619-93-6 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-diphenyl-, (4'R,4aS,5'R)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.



RN 787620-00-2 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4',4a,6'-trimethyl-, (4'R,4aS,6'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787620-02-4 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,5'-trimethyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787620-09-1 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,6'-trimethyl-, (4'R,4aS,6'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787620-10-4 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,6'-trimethyl-, (4'R,4aS,6'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 858371-54-7 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a-dimethyl-, (2'S,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 858371-55-8 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a-dimethyl-, (2'R,4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 858371-57-0 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4',4a,6',6'-pentamethyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 786708-00-7P 786708-30-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(novel ketal ligands for glucocorticoid receptor and in vitro and in vivo activity)
RN 786708-00-7 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-30-3 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:927012 CAPLUS
DN 141:395547
TI Preparation of selective spirocyclic glucocorticoid receptor modulators
IN Ali, Amjad; Balkovec, James M.; Beresis, Richard; Colletti, Steven L.; Graham, Donald W.; Patel, Gool F.; Smith, Cameron J.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 201 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004093805	A2	20041104	WO 2004-US12102	20040419
	WO 2004093805	A3	20051208		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

	AU 2004232301	A1	20041104	AU 2004-232301	20040419
	CA 2522946	A1	20041104	CA 2004-2522946	20040419
	EP 1617806	A2	20060125	EP 2004-760029	20040419
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1809347	A	20060726	CN 2004-80017051	20040419
	JP 2006524251	T	20061026	JP 2006-513140	20040419
	US 2006217563	A1	20060928	US 2005-551933	20051004
PRAI	US 2003-464784P	P	20030423		
	WO 2004-US12102	W	20040419		

OS MARPAT 141:395547
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Ring A = carbocyclyl or heterocyclyl; m = 0-3; n = 0-2; R1 = (un)substituted-alkyl, -alkenyl, -alkynyl, -cycloalkyl, etc.; R2 and R3 independently = H, halo, alkyl, aryl, etc.; R4 = OH, CO2H, (un)substituted-alkyl, -Ph, etc.] , as well as their pharmaceutically acceptable salts or hydrates thereof, are prepared and disclosed as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Thus, e.g., II was prepared via spirocyclization of III (preparation given) with Et α-bromomethyl acrylate. In human glucocorticoid receptor assays, I demonstrated a range of GR affinity with IC50 values between 10 μM and 1 nM. Pharmaceutical compns. and methods of use are also included.

IT 786706-22-7P 786706-34-1P 786706-35-2P
786706-42-1P 786706-43-2P 786706-45-4P
786706-49-8P 786706-50-1P 786706-56-7P
786706-62-5P 786707-01-5P 786707-07-1P
786707-08-2P 786707-10-6P 786707-14-0P
786707-16-2P 786707-19-5P 786707-23-1P
786707-24-2P 786707-26-4P 786707-28-6P
786707-52-6P 786707-53-7P 786707-54-8P
786707-55-9P 786707-56-0P 786707-57-1P
786707-62-8P 786708-06-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazoles bearing annulated spirocyclic hydronaphthalene derivs. as glucocorticoid receptor modulators)

RN 786706-22-7 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 1-(4-fluorophenyl)-1,4,4',4a,5',6,7,8-octahydro-4a-methyl-4'-methylene-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-34-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[2H]pyran]-6'-ol, 1-(4-fluorophenyl)-1,3',4,4',4a,5',6,6',7,8-decahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-35-2 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[2H]pyran]-6'-ol, 1-(4-fluorophenyl)-3',4,4',4a,5',6,6',7-octahydro-4a-methyl-, (2'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-42-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan]-5'-ol, 1-(4-fluorophenyl)-

1,4,4',4a,5',6,7,8-octahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-43-2 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(5'H)-furan]-5'-one, 1-(4-fluorophenyl)-1,3',4,4',4a,6,7,8-octahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-45-4 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(5'H)-furan]-5'-one, 1-(4-fluorophenyl)-1,3',4,4',4a,6,7,8-octahydro-4a-methyl-4',4'-bis(phenylmethyl)-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-49-8 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'(5'H)-furan]-5'-one, 1-(4-fluorophenyl)-3',4,4',4a,6,7-hexahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-50-1 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'(5'H)-furan]-5'-one, 1-(4-fluorophenyl)-3',4,4',4a,6,7-hexahydro-4a-methyl-4',4'-di-2-propenyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-56-7 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4'-phenyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-62-5 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(5'H)-furan], 4'-ethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-01-5 CAPLUS
CN Spiro[5H-benz[f]indazole-5,5'-oxazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-07-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,5'-oxazolidine]-3'-acetic acid, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2'-oxo-, ethyl ester, (4aS,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-08-2 CAPLUS

CN Spiro[5H-benz[f]indazole-5,5'-oxazolidin]-2'-one, 3'-[2-(1,3-dioxan-2-yl)ethyl]-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS,5S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-10-6 CAPLUS
CN Benzoic acid, 4-[(4aS,5S)-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2'-oxospiro[5H-benz[f]indazole-5,5'-oxazolidin]-3'-yl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-14-0 CAPLUS
CN Spiro[5H-benz[f]indazole-5,5'-oxazolidine]-3'-acetic acid, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2'-oxo-, (4aS,5S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-16-2 CAPLUS
CN Spiro[5H-benz[f]indazole-5,5'-oxazolidine]-3'-propanal, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2'-oxo-, (4aS,5S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-19-5 CAPLUS
CN Spiro[5H-benz[f]indazole-5,5'-oxazolidine]-3'-propanoic acid, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2'-oxo-, (4aS,5S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-23-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-24-2 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-26-4 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-3'-(phenylmethyl)-, (4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-28-6 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-5'-thioxo-, (4'S,4aS)- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.



RN 786707-52-6 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 786707-53-7 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolan]-8(4H)-one, 1-(4-fluorophenyl)-1,4a,6,7-tetrahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-54-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolan]-8-ol, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a,8-dimethyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-55-9 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-56-0 CAPLUS
CN Spiro[cyclopent[f]indazole-5(6H),2'-[1,3]dioxolan]-7(1H)-one, 1-(4-fluorophenyl)-4,4a-dihydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-57-1 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a-dihydro-4a,7-dimethyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-62-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-(phenylmethyl)-, (4'R,4aS,5'R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-06-3 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 4',5'-diethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 571203-14-0P 614762-99-1P 786706-23-8P
786706-24-9P 786706-25-0P 786706-26-1P
786706-29-4P 786706-30-7P 786706-31-8P
786706-32-9P 786706-36-3P 786706-37-4P
786706-38-5P 786706-39-6P 786706-40-9P
786706-44-3P 786706-46-5P 786706-47-6P
786706-51-2P 786706-55-6P 786706-57-8P
786706-58-9P 786706-59-0P 786706-60-3P
786706-63-6P 786706-64-7P 786706-65-8P

786706-66-9P 786706-67-0P 786706-68-1P
786706-69-2P 786706-70-5P 786706-71-6P
786706-72-7P 786706-73-8P 786706-74-9P
786706-75-0P 786706-76-1P 786706-77-2P
786706-78-3P 786706-79-4P 786706-80-7P
786706-81-8P 786706-82-9P 786706-83-0P
786706-84-1P 786706-85-2P 786706-86-3P
786706-90-9P 786706-96-5P 786706-97-6P
786706-98-7P 786706-99-8P 786707-02-6P
786707-03-7P 786707-04-8P 786707-05-9P
786707-06-0P 786707-09-3P 786707-11-7P
786707-12-8P 786707-13-9P 786707-15-1P
786707-17-3P 786707-18-4P 786707-20-8P
786707-21-9P 786707-22-0P 786707-25-3P
786707-27-5P 786707-29-7P 786707-30-0P
786707-31-1P 786707-32-2P 786707-33-3P
786707-34-4P 786707-35-5P 786707-36-6P
786707-37-7P 786707-38-8P 786707-39-9P
786707-40-2P 786707-41-3P 786707-42-4P
786707-43-5P 786707-44-6P 786707-45-7P
786707-46-8P 786707-47-9P 786707-48-0P
786707-49-1P 786707-50-4P 786707-51-5P
786707-58-2P 786707-59-3P 786707-60-6P
786707-61-7P 786707-63-9P 786707-64-0P
786707-65-1P 786707-66-2P 786707-67-3P
786707-68-4P 786707-69-5P 786707-70-8P
786707-71-9P 786707-72-0P 786707-73-1P
786707-74-2P 786707-75-3P 786707-76-4P
786707-77-5P 786707-78-6P 786707-79-7P
786707-80-0P 786707-81-1P 786707-82-2P
786707-83-3P 786707-84-4P 786707-85-5P
786707-86-6P 786707-87-7P 786707-88-8P
786707-89-9P 786707-90-2P 786707-91-3P
786707-94-6P 786707-95-7P 786707-96-8P
786707-97-9P 786707-98-0P 786707-99-1P
786708-00-7P 786708-01-8P 786708-02-9P
786708-03-0P 786708-04-1P 786708-05-2P
786708-07-4P 786708-08-5P 786708-09-6P
786708-10-9P 786708-11-0P 786708-12-1P
786708-13-2P 786708-14-3P 786708-15-4P
786708-16-5P 786708-17-6P 786708-18-7P
786708-19-8P 786708-20-1P 786708-21-2P
786708-22-3P 786708-23-4P 786708-24-5P
786708-25-6P 786708-26-7P 786708-27-8P
786708-28-9P 786708-29-0P 786708-30-3P
786708-31-4P 786708-32-5P 786708-33-6P
786708-34-7P 786708-35-8P 786708-36-9P
786708-37-0P 786708-38-1P 786708-39-2P
786708-40-5P 786708-41-6P 786708-42-7P
786708-43-8P 786708-44-9P 786708-45-0P
786708-46-1P 786708-47-2P 786708-48-3P
786708-49-4P 786708-50-7P 786708-51-8P
786708-52-9P 786708-53-0P 786708-54-1P
786708-55-2P 786708-56-3P 786708-58-5P
786708-61-0P 786708-64-3P 786708-67-6P
786708-70-1P 786708-73-4P 786708-75-6P
786708-77-8P 786708-79-0P 786708-81-4P
786708-83-6P 786708-85-8P 786709-54-4P
786709-55-5P 786709-57-7P 786709-58-8P
787619-78-7P 787619-79-8P 787619-80-1P
787619-81-2P 787619-82-3P 787619-83-4P
787619-84-5P 787619-85-6P 787619-86-7P
787619-87-8P 787619-88-9P 787619-90-3P
787619-92-5P 787619-93-6P 787619-95-8P

787619-97-0P 787619-99-2P 787620-00-2P
787620-01-3P 787620-02-4P 787620-03-5P
787620-04-6P 787620-05-7P 787620-06-8P
787620-07-9P 787620-08-0P 787620-09-1P
787620-10-4P 787620-11-5P 787620-12-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazoles bearing annulated spirocyclic hydronaphthalene derivs. as glucocorticoid receptor modulators)

RN 571203-14-0 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl- (9CI) (CA INDEX NAME)



RN 614762-99-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-23-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 1-(4-fluorophenyl)-1,4,4',4a,5',6,7,8-octahydro-4',4a-dimethyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-24-9 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan]-4'-ol, 1-(4-fluorophenyl)-1,4,4',4a,5',6,7,8-octahydro-4',4a-dimethyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-25-0 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan]-5'(4'H)-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4'-methylene-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-26-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(5'H)-furan]-5'-one, 1-(4-fluorophenyl)-1,3',4,4',4a,6,7,8-octahydro-4a-methyl-4'-methylene-, (2'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-29-4 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[2H]pyran], 1-(4-fluorophenyl)-1,3',4,4a,6,6',7,8-octahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-30-7 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[2H]pyran], 1-(4-fluorophenyl)-1,3',4,4a,6,6',7,8-octahydro-4a,5'-dimethyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-31-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[2H]pyran]-5'-carboxylic acid, 1-(4-fluorophenyl)-1,3',4,4a,6,6',7,8-octahydro-4a-methyl-, methyl ester, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-32-9 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[2H]pyran]-5'-methanol, 1-(4-fluorophenyl)-1,3',4,4a,6,6',7,8-octahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-36-3 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[2H]pyran], 1-(4-fluorophenyl)-1,3',4,4',4a,5',6,6',7,8-decahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-37-4 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[2H]pyran], 1-(4-fluorophenyl)-3',4,4',4a,5',6,6',7-octahydro-4a-methyl-, (2'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-38-5 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[2H]pyran], 1-(4-fluorophenyl)-1,3',4,4',4a,5',6,6',7,8-decahydro-4a,6'-dimethyl-, (2'R,4aS,6'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-39-6 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[2H]pyran], 6'-ethyl-1-(4-fluorophenyl)-1,3',4,4',4a,5',6,6',7,8-decahydro-4a-methyl-, (2'R,4aS,6'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-40-9 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[2H]pyran], 1-(4-fluorophenyl)-3',4,4',4a,5',6,6',7-octahydro-4a,6'-dimethyl-, (2'S,4aS,6'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-44-3 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 1-(4-fluorophenyl)-1,4,4',4a,5',6,7,8-octahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-46-5 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan]-5'-ol, 1-(4-fluorophenyl)-1,4,4',4a,5',6,7,8-octahydro-4a-methyl-4',4'-bis(phenylmethyl)-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-47-6 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 1-(4-fluorophenyl)-1,4,4',4a,5',6,7,8-octahydro-4a-methyl-4',4'-bis(phenylmethyl)-5'-(2-propenyl)-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-51-2 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'(5'H)-furan]-5'-one, 1-(4-fluorophenyl)-3',4,4',4a,6,7-hexahydro-4a-methyl-4',4'-dipropyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-55-6 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(5'H)-furan], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4'-phenyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-57-8 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'(5'H)-furan], 4'-ethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-58-9 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'(5'H)-furan], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4'-phenyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-59-0 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'(5'H)-furan], 1,4'-bis(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-60-3 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(5'H)-furan], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4'-(phenylmethyl)-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-63-6 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(5'H)-furan], 4'-ethyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-64-7 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 1-(4-fluorophenyl)-1,4,4',4a,5',6,7,8-octahydro-4a-methyl-4'-phenyl-, (2'R,4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-65-8 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'(5'H)-furan]-5'-one, 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-66-9 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'(3'H)-furan], 1-(4-fluorophenyl)-4,4',4a,5',6,7-hexahydro-4a-methyl-4',4'-dipropyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-67-0 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'(3'H)-furan]-5'-ol, 1-(4-fluorophenyl)-4,4',4a,5',6,7-hexahydro-4a-methyl-4',4'-dipropyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-68-1 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'(3'H)-furan], 1-(4-fluorophenyl)-4,4',4a,5',6,7-hexahydro-4a-methyl-4',4'-di-2-propenyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-69-2 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'(3'H)-furan]-5'-ol,

1-(4-fluorophenyl)-4,4',4a,5',6,7-hexahydro-4a-methyl-4',4'-di-2-propenyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-70-5 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'(3'H)-furan], 1-(4-fluorophenyl)-4,4',4a,5',6,7-hexahydro-4',4',4a-trimethyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-71-6 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'(3'H)-furan]-5'-ol, 1-(4-fluorophenyl)-4,4',4a,5',6,7-hexahydro-4',4',4a-trimethyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-72-7 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'(5'H)-furan]-5'-one, 1-(4-fluorophenyl)-3',4,4',4a,6,7-hexahydro-4',4',4a-trimethyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-73-8 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'(3'H)-furan], 1-(4-fluorophenyl)-4,4',4a,5',6,7-hexahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-74-9 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'(3'H)-furan]-5'-ol, 1-(4-fluorophenyl)-4,4',4a,5',6,7-hexahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-75-0 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 5'-ethyl-1-(4-fluorophenyl)-1,4,4',4a,5',6,7,8-octahydro-4a-methyl-, (2'S,4aS,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-76-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 5'-ethyl-1-(4-fluorophenyl)-1,4,4',4a,5',6,7,8-octahydro-4a-methyl-, (2'S,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-77-2 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 1-(4-fluorophenyl)-1,4,4',4a,5',6,7,8-octahydro-4a-methyl-5'-phenyl-, (2'S,4aS,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-78-3 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 1-(4-fluorophenyl)-1,4,4',4a,5',6,7,8-octahydro-4a-methyl-4',4',5'-tri-2-propenyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-79-4 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 1-(4-fluorophenyl)-1,4,4',4a,5',6,7,8-octahydro-4',4',4a-trimethyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-80-7 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 1-(4-fluorophenyl)-1,4,4',4a,5',6,7,8-octahydro-4a-methyl-4',4'-bis(phenylmethyl)-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-81-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 1-(4-fluorophenyl)-1,4,4',4a,5',6,7,8-octahydro-4a-methyl-4',4'-di-2-propenyl-, (2'R,4aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-82-9 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan]-5'-ol, 1-(4-fluorophenyl)-1,4,4',4a,5',6,7,8-octahydro-4',4',4a-trimethyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-83-0 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan]-5'-ol, 1-(4-fluorophenyl)-1,4,4',4a,5',6,7,8-octahydro-4a-methyl-4',4'-di-2-propenyl-, (2'R,4aS)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-84-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 1-(4-fluorophenyl)-1,4,4',4a,5',6,7,8-octahydro-4a-methyl-5'-(2-propenyl)-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-85-2 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(5'H)-furan]-5'-one, 1-(4-fluorophenyl)-1,3',4,4',4a,6,7,8-octahydro-4',4',4a-trimethyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-86-3 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'(5'H)-furan]-5'-one, 1-(4-fluorophenyl)-1,3',4,4',4a,6,7,8-octahydro-4a-methyl-4',4'-di-2-propenyl-, (2'R,4aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-90-9 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-pyrrolidin]-5'-one, 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-96-5 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),3'-pyrrolidine], 1'-(ethylsulfonyl)-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (3'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-97-6 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),3'-pyrrolidine], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-1'-(phenylsulfonyl)-, (3'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-98-7 CAPLUS
CN Spiro[5H-benz[f]indazole-5,3'-pyrrolidine], 1'-(ethylsulfonyl)-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (3'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-99-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,3'-pyrrolidine], 1-(4-fluorophenyl)-

1,4,4a,6,7,8-hexahydro-4a-methyl-1'-(phenylsulfonyl)-, (3'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-02-6 CAPLUS
CN Spiro[5H-benz[f]indazole-5,5'-oxazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-3'-(phenylmethyl)-, (4aS,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-03-7 CAPLUS
CN Spiro[5H-benz[f]indazole-5,5'-oxazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-3',4a-dimethyl-, (4aS,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-04-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,5'-oxazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-3'-(2-propenyl)-, (4aS,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-05-9 CAPLUS
CN Spiro[5H-benz[f]indazole-5,5'-oxazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-3'-(1-methylethyl)-, (4aS,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-06-0 CAPLUS
CN Spiro[5H-benz[f]indazole-5,5'-oxazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-3'-(2-methoxyethyl)-4a-methyl-, (4aS,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-09-3 CAPLUS
CN Spiro[5H-benz[f]indazole-5,5'-oxazolidin]-2'-one, 3'-acetyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-11-7 CAPLUS
CN Benzoic acid, 4-[(4aS,5S)-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2'-oxospiro[5H-benz[f]indazole-5,5'-oxazolidin]-3'-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-12-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,5'-oxazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-3'-phenyl-, (4aS,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-13-9 CAPLUS
CN Benzoic acid, 3-[(4aS,5S)-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2'-oxospiro[5H-benz[f]indazole-5,5'-oxazolidin]-3'-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-15-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,5'-oxazolidine]-3'-acetamide, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2'-oxo-N-phenyl-, (4aS,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-17-3 CAPLUS
CN Spiro[5H-benz[f]indazole-5,5'-oxazolidin]-2'-one, 3'-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-

, (4aS,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-18-4 CAPLUS
CN Spiro[5H-benz[f]indazole-5,5'-oxazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-3'-(3-hydroxypropyl)-4a-methyl-, (4aS,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-20-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,5'-oxazolidine]-3'-propanamide, N-cyano-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2'-oxo-, (4aS,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-21-9 CAPLUS
CN Spiro[5H-benz[f]indazole-5,5'-oxazolidine]-3'-propanamide, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-N-(methylsulfonyl)-2'-oxo-, (4aS,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-22-0 CAPLUS
CN Spiro[5H-benz[f]indazole-5,5'-oxazolidine]-3'-propanamide, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2'-oxo-N-(phenylsulfonyl)-, (4aS,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-25-3 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-3',4a-dimethyl-, (4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-27-5 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-1',4a-dimethyl-3'-(phenylmethyl)-, (4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-29-7 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-30-0 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-3',4a-dimethyl-, (4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-31-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-3',4a-dimethyl-1'-(phenylmethyl)-, (4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-32-2 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-1',3',4a-trimethyl-, (4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-33-3 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-3',4a-dimethyl-1'-(2-propenyl)-, (4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-34-4 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-3',4a-dimethyl-1'-(phenylmethyl)-, (4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-35-5 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-1',3',4a-trimethyl-, (4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-36-6 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione,

1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-3',4a-dimethyl-1'-(2-propenyl)-, (4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-37-7 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-1'-propanoic acid, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2',5'-dioxo-3'-(phenylmethyl)-, (4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-38-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-3'-propanoic acid, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2',5'-dioxo-, (4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-39-9 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione, 3'-[2-(1,3-dioxan-2-yl)ethyl]-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-40-2 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-1'-propanoic acid, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-3',4a-dimethyl-2',5'-dioxo-, (4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-41-3 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione, 1'-[2-(1,3-dioxan-2-yl)ethyl]-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-3',4a-dimethyl-, (4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-42-4 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-1',3'-di-2-propenyl-, (4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-43-5 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-1',3'-bis(phenylmethyl)-, (4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-44-6 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-3'-(phenylmethyl)-5'-thioxo-, (4'R,4aS)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-45-7 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-5'-thioxo-, (4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-46-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-3'-(2-propenyl)-5'-thioxo-, (4'R,4aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-47-9 CAPLUS

CN Spiro[5H-benz[f]indazole-5,4'-imidazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-3',4a-dimethyl-5'-thioxo-, (4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-48-0 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-3'-(phenylmethyl)-, (4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-49-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-50-4 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-1',3',4a-trimethyl-, (4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-51-5 CAPLUS
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-3',4a-dimethyl-, (4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-58-2 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4'-(methoxymethyl)-4a-methyl-, (2'R,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-59-3 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4'-(methoxymethyl)-4a-methyl-, (2'R,4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-60-6 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4'-(methoxymethyl)-4a-methyl-, (2'S,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-61-7 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4'-(methoxymethyl)-4a-methyl-, (2'S,4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-63-9 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4',4a,5'-trimethyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-64-0 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl- (9CI) (CA INDEX NAME)



RN 786707-65-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-66-2 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-dipropyl- (9CI) (CA INDEX NAME)



RN 786707-67-3 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-dipropyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-68-4 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-dibutyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-69-5 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxane], 4'-(1-ethylpropyl)-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-6'-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 786707-70-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-71-9 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-di-1-propenyl-, (4'R,4aS,5'R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 786707-72-0 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane]-4',5'-dicarboxylic acid, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, dimethyl ester,

(4'S,4aS,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-73-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-furo[3,4-d][1,3]dioxol]-4'(3'aH)-one, 1-(4-fluorophenyl)-1,4,4a,6,6',6'a,7,8-octahydro-4a-methyl-, (3'aR,6'aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-74-2 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]benzodioxole], 1-(4-fluorophenyl)-1,3'a,4,4',4a,5',6,6',7,7',7'a,8-dodecahydro-4a-methyl-, (3'aR,4aS,7'aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-75-3 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-naphtho[1,2-d][1,3]dioxole], 1-(4-fluorophenyl)-1,3'a,4,4',4a,5',6,7,8,9'b-decahydro-4a-methyl-, (3'aR,9'bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 786707-76-4 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-naphtho[2,3-d][1,3]dioxole], 1-(4-fluorophenyl)-1,3'a,4,4',4a,6,7,8,9',9'a-decahydro-4',4',4a,9',9'-pentamethyl- (9CI) (CA INDEX NAME)



RN 786707-77-5 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-dicyclohexyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-78-6 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-diphenyl-, (4'R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-79-7 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-bis(2-chlorophenyl)-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-80-0 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4',5'-bis(methoxymethyl)-4a-methyl-, (4'R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-81-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-bis[(phenylmethoxy)methyl]-, (4'R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-82-2 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-bis[[(4-chlorophenyl)methoxy]methyl]-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-83-3 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4',4a-dimethyl-, (4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-84-4 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4'-ethyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-85-5 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4'-propyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-86-6 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4'-(1,1-dimethylethyl)-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-87-7 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-88-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-89-9 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (2'R,4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-90-2 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (2'S,4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-91-3 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4'-(5-hexenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-94-6 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4'-(ethoxymethyl)-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-95-7 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4'-[(2-propenyloxy)methyl]-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-96-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4'-[(methylthio)methyl]-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-97-9 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dithiolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl- (9CI) (CA INDEX NAME)



RN 786707-98-0 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dithiolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4',4a,5'-trimethyl- (9CI) (CA INDEX NAME)



RN 786707-99-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl- (9CI) (CA INDEX NAME)



RN 786708-00-7 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-01-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a,5',5'-trimethyl- (9CI) (CA INDEX NAME)



RN 786708-02-9 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a,5',5'-trimethyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-03-0 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4',4a,6'-trimethyl-, (4'S,4aS,6'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-04-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dithiane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl- (9CI) (CA INDEX NAME)



RN 786708-05-2 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,5'-trimethyl-, (4'S,4aS,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-07-4 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4',5'-di-(1E)-1-propenyl-, (4'R,4aS,5'R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 786708-08-5 CAPLUS
CN 2-Propenoic acid, 3,3'-[(4'S,4aS,5'S)-1-(4-fluorophenyl)-4,4a,6,7-tetrahydrospiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane]-4',5'-diyl]bis-, dimethyl ester, (2E,2'E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 786708-09-6 CAPLUS
CN Spiro[1,3-benzodioxole-2,5'(1'H)-cyclopent[f]indazole], 1'-(4-fluorophenyl)-3a,4,4',4'a,5,6,6',7,7',7a-decahydro-4'a-methyl-, (3aR,4'aS,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-10-9 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4',5'-diphenyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-11-0 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',5'-bis(methoxymethyl)-4a-methyl-, (4'R,4aS,5'R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-12-1 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a-dimethyl-, (2'R,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-13-2 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a-dimethyl-, (2'S,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-14-3 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'R,4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-15-4 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'S,4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-16-5 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'R,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-17-6 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'S,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-18-7 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-

4,4a,6,7-tetrahydro-4a-methyl-4'-phenyl-, (2'S,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-19-8 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4'-phenyl-, (2'R,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-20-1 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4'-phenyl-, (2'R,4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-21-2 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4'-phenyl-, (2'S,4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-22-3 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a-dimethyl-4'-phenyl-, (2'R,4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-23-4 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a-dimethyl-4'-phenyl-, (2'R,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-24-5 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a-dimethyl-4'-phenyl-, (2'S,4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-25-6 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a-dimethyl-4'-phenyl-, (2'S,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-26-7 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4'-(methoxymethyl)-4a-methyl-, (2'R,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-27-8 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4'-(methoxymethyl)-4a-methyl-, (2'R,4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-28-9 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4'-(methoxymethyl)-4a-methyl-, (2'S,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-29-0 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4'-(methoxymethyl)-4a-methyl-, (2'S,4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-30-3 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-31-4 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a-dimethyl-, (4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-32-5 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a-dimethyl-, (4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-33-6 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,6'-trimethyl-, (4'S,4aS,6'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-34-7 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a,5',5'-trimethyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-35-8 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4',4a,6'-tetramethyl-, (2'R,4aS,6'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-36-9 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4',4a,6'-tetramethyl-, (2'S,4aS,6'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-37-0 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dithiane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-38-1 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dithiane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a-dimethyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-39-2 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-(phenylmethyl)-, (4'S,4aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-40-5 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-(phenylmethyl)-, (2'S,4'S,4aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-41-6 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-(phenylmethyl)-, (2'R,4'S,4aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-42-7 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4',6'-dimethyl-4a-(phenylmethyl)-, (4'S,4aS,6'S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-43-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1-(4-fluorophenyl)-1,4,4a,6-tetrahydro-4a,8-dimethyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-44-9 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6-tetrahydro-4a,8-dimethyl-4',5'-diphenyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-45-0 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 4',5'-diethyl-1-(4-

fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, stereoisomer (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-46-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-(phenylmethyl)-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-47-2 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1,4,4a,6,7,8-hexahydro-4a-methyl-1-phenyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-48-3 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1,4,4a,6,7,8-hexahydro-4a-methyl-1-(4-pyridinyl)-, (4'R,5'R)- (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



RN 786708-49-4 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1-(3-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-50-7 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1,4,4a,6,7,8-hexahydro-4a-methyl-1-(phenylmethyl)-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-51-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-cyclopentyl-4',5'-diethenyl-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-52-9 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-cyclohexyl-4',5'-diethenyl-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-53-0 CAPLUS
CN Acetamide, N-[4-(4',5'-diethenyl-1,4,4',4a,5',6,7,8-octahydro-4a-methylspiro[5H-benz[f]indazole-5,2'-[1,3]dioxolan]-1-yl)phenyl]-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-54-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-chlorophenyl)-4',5'-diethenyl-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-55-2 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1,4,4a,6,7,8-hexahydro-4a-methyl-1-[4-(1-methylethoxy)phenyl]-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-56-3 CAPLUS
CN Carbamic acid, dimethyl-, 4-[(4'R,4aS,5'R)-4',5'-diethenyl-1,4,4',4a,5',6,7,8-octahydro-4a-methylspiro[5H-benz[f]indazole-5,2'-[1,3]dioxolan]-1-yl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-58-5 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 4-[(4'R,4aS,5'R)-4',5'-diethenyl-1,4,4',4a,5',6,7,8-octahydro-4a-methylspiro[5H-benz[f]indazole-5,2'-[1,3]dioxolan]-1-yl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-61-0 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(3,4-dichlorophenyl)-4',5'-diethenyl-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-64-3 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1,4,4a,6,7,8-hexahydro-1-(4-methoxyphenyl)-4a-methyl-, (4'R,4aS,5'R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-67-6 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1,4,4a,6,7,8-hexahydro-4a-methyl-1-(4-methylphenyl)-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-70-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1,4,4a,6,7,8-hexahydro-4a-methyl-1-[4-(trifluoromethyl)phenyl]-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-73-4 CAPLUS
CN Benzoic acid, 4-[(4'R,4aS,5'R)-4',5'-diethenyl-1,4,4',4a,5',6,7,8-octahydro-4a-methylspiro[5H-benz[f]indazole-5,2'-[1,3]dioxolan]-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-75-6 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-cyclopentyl-1,4,4a,6,7,8-hexahydro-4a-methyl- (9CI) (CA INDEX NAME)



RN 786708-77-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1,4,4a,6,7,8-hexahydro-1-(4-methoxyphenyl)-4a-methyl- (9CI) (CA INDEX NAME)



RN 786708-79-0 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1,4,4a,6,7,8-hexahydro-4a-methyl-1-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 786708-81-4 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1,4,4a,6,7,8-hexahydro-4a-methyl-1-phenyl- (9CI) (CA INDEX NAME)



RN 786708-83-6 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1,4,4a,6,7,8-hexahydro-4',4a,5'-trimethyl-1-phenyl-, (4'R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-85-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1,4,4a,6,7,8-hexahydro-4',4a,5'-trimethyl-1-(4-pyridinyl)-, (4'R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786709-54-4 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4'-phenyl-, (2'R,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786709-55-5 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4'-phenyl-, (2'S,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786709-57-7 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4'-phenyl-, (2'S,4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786709-58-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4'-phenyl-, (2'R,4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787619-78-7 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4',4a,5'-trimethyl-, (4'α,5'β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 787619-79-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4',4a,5'-trimethyl-, (4'R,4aS,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787619-80-1 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4',4a,5'-trimethyl-, (4'S,4aR,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787619-81-2 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4',4a,5'-trimethyl-, (4'S,4aS,5'S)- (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



RN 787619-82-3 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'α,5'α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 787619-83-4 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-dipropyl-, (4'α,5'α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 787619-84-5 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'α,5'α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 787619-85-6 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-di-1-propynyl-, (4'R,4aS,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787619-86-7 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane]-4',5'-dicarboxylic acid, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, dimethyl ester, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787619-87-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[6H]cyclopenta[1,3]dioxole], 1-(4-fluorophenyl)-1,3'a,4,4',4a,5',6,6'a,7,8-decahydro-4a-methyl-, (3'aR,6'aS)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 787619-88-9 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[6H]cyclopenta[1,3]dioxole], 1-(4-fluorophenyl)-1,3'a,4,4',4a,5',6,6'a,7,8-decahydro-4a-methyl-, (3'aR,4aS,6'aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787619-90-3 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]benzodioxole], 1-(4-fluorophenyl)-1,3'a,4,4',4a,5',6,6',7,7',7'a,8-dodecahydro-4a-methyl-, (3'aR,4aS,7'aS)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 787619-92-5 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-diphenyl-, (4'α,5'α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 787619-93-6 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-diphenyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787619-95-8 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-bis(2-chlorophenyl)-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'S,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787619-97-0 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4',5'-bis(methoxymethyl)-4a-methyl-, (4'S,5'S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787619-99-2 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4',5'-bis(methoxymethyl)-4a-methyl-, (4'S,4aS,5'S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787620-00-2 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4',4a,6'-trimethyl-, (4'R,4aS,6'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787620-01-3 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4',4a,6'-trimethyl-, (4'R,4aS,6'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787620-02-4 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,5'-trimethyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787620-03-5 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,5'-trimethyl-, (4aS,2'α,4'α,5'.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787620-04-6 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,5'-trimethyl-, (4aS,2'α,4'β,5'β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787620-05-7 CAPLUS
CN Spiro[4H-cyclopenta-1,3-dioxole-2,5'(1'H)-cyclopent[f]indazole], 1-(4-fluorophenyl)-3'a,4,4',4a,5',6,6'a,7-octahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787620-06-8 CAPLUS
CN Spiro[1,3-benzodioxole-2,5'(1'H)-cyclopent[f]indazole], 1'-(4-fluorophenyl)-3a,4,4',4'a,5,6,6',7,7',7a-decahydro-4'a-methyl-, (3aS,4'aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787620-07-9 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',5'-bis(methoxymethyl)-4a-methyl-, (4'S,4aS,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787620-08-0 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dithiolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,5'-trimethyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787620-09-1 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,6'-trimethyl-, (4'R,4aS,6'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787620-10-4 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,6'-trimethyl-, (4'R,4aS,6'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787620-11-5 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1,4,4a,6,7,8-hexahydro-4a-methyl-1-phenyl-, (4'R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787620-12-6 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-[6H]cyclopenta[1,3]dioxole], 1,3'a,4,4',4a,5',6,6'a,7,8-decahydro-4a-methyl-1-phenyl-, (3'aR,4aS,6'aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 790220-33-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazoles bearing annulated spirocyclic hydronaphthalene derivs. as glucocorticoid receptor modulators)
RN 790220-33-6 CAPLUS
CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dithiolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,5'-trimethyl-, (4'R,4aS,5'S)- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.



IT 786706-54-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazoles bearing annulated spirocyclic hydronaphthalene derivs. as glucocorticoid receptor modulators)
RN 786706-54-5 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'(5'H)-furan], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4'-(tributylstannyl)-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:740124 CAPLUS
DN 141:260743
TI Preparation of cyclopent[f]indazole and benz[f]indazole derivatives selective non-steroidal glucocorticoid receptor.modulators
IN Ali, Amjad; Beresis, Richard; Colletti, Steven L.; Graham, Donald W.; Tata, James R.; Thompson, Christopher F.
PA Merck & Co. Inc., USA
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004075840	A2	20040910	WO 2004-US5199	20040220
	WO 2004075840	A3	20050203		

WO 2004075840 A9 20050804
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004216182	A1	20040910	AU 2004-216182	20040220
CA 2516684	A1	20040910	CA 2004-2516684	20040220
EP 1599201	A2	20051130	EP 2004-713398	20040220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006518752	T	20060817	JP 2006-503780	20040220
US 2006074120	A1	20060406	US 2005-544899	20050808
PRAI US 2003-450811P	P	20030225		
WO 2004-US5199	W	20040220		

OS MARPAT 141:260743

GI



I



II

AB Title compds. represented by the formula I [wherein J = NR1, CR1R2; K = NR3, CR3R4; L = NR5, CR5R6; X = hydroxy, alkoxy, carbamoyl, etc.; R1-R6 = independently H, halo, (cyclo)alkyl, etc.; R7 = H, hydroxy, alkoxy, aryl, etc.; R8 = (cyclo)alkyl, alkenyl, alkynyl, etc.; R9, R10 = independently halo, hydroxy, alkyl, alkenyl, alkoxy; n = 0-2; and pharmaceutically acceptable salts or hydrates thereof] were prepared as selective non-steroidal glucocorticoid receptor modulators. For example, II was given in a multi-steps synthesis starting from 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-cyclopent[f]indazol-5(1H)-one reacting with phenylethynylmagnesium bromide. I showed affinity of glucocorticoid receptor with IC50 values between 10 μM and 1 nM. Thus, I and their pharmaceutical compns. are useful for the treatment of a variety of autoimmune and inflammatory diseases or conditions.

IT 614762-99-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of cyclopent[f]indazol-5-yl and benz[f]indazol-5-yl derivs. as selective non-steroidal glucocorticoid receptor modulators)

RN 614762-99-1 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:270010 CAPLUS

DN 140:287380

TI Preparation of octahydro-2-H-naphtho[1,2-f]indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators for the treatment of autoimmune and inflammatory conditions

IN Ali, Amjad; Aster, Susan D.; Balkovec, James M.; Graham, Donald W.; Hunt, Julianne A.; Kallashi, Florida; Sinclair, Peter J.; Tata, James R.; Taylor, Gayle E.; Goulet, Joung L.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 170 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026248	A2	20040401	WO 2003-US29494	20030917
	WO 2004026248	A3	20040715		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2499150	A1	20040401	CA 2003-2499150	20030917
	AU 2003270783	A1	20040408	AU 2003-270783	20030917
	EP 1542996	A2	20050622	EP 2003-752495	20030917
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006503107	T	20060126	JP 2004-568945	20030917
	US 2005245588	A1	20051103	US 2005-527615	20050311
PRAI	US 2002-412231P	P	20020920		
	US 2003-476079P	P	20030605		
	WO 2003-US29494	W	20030917		

OS MARPAT 140:287380

GI



I



II

AB Octahydro-2-H-naphtho[1,2-f]indole-4-carboxamide derivs. I (X = CO, NHCO, CONH, NH, CH2NH; R1,R2 = H, alkyl, alkenyl, cycloalkyl, alkoxy, aryl; R3 = alkyl, alkoxy, acid, halogen substituted alkyl; R4 = alkyl, alkenyl, cycloalkoxy, alkoxy, aryl) were prepared as selective glucocorticoid receptor modulators for the treatment of autoimmune and inflammatory conditions. Thus, (S)-Wieland-Miescher ketone was protected as the ketal using p-toluene sulfonic acid and ethylene glyclol and then treated with Et formate to give the hydroxymethylene ketal derivative The hydroxymethylene was dissolved in acetic acid and reacted with p-fluorophenyl hydrazine hydrochloride to give II. The ketal of II was converted to the ketone using 6N HCl, and the resulting ketone transformed into the triflate. The triflate was treated with tributylvinyl tin and PPh3 to give the corresponding coupling product. Treatment with ethyl-4,4,4-trifluorocrotonate followed by dropwise addition of BCl3 gave the target I (R1 = CF3, R2, R3 = H, X = CO, R4 = OEt),.

IT 614762-99-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of octahydronaphthoindole-4-carboxamide derivs. as selective glucocorticoid receptor modulators for the treatment of autoimmune and inflammatory conditions)

RN 614762-99-1 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:267662 CAPLUS

DN 141:7063

TI Novel N-Arylpyrazolo[3,2-c]-Based Ligands for the Glucocorticoid Receptor: Receptor Binding and in Vivo Activity

AU Ali, Amjad; Thompson, Christopher F.; Balkovec, James M.; Graham, Donald W.; Hammond, Milton L.; Quraishi, Nazia; Tata, James R.; Einstein, Monica; Ge, Lan; Harris, Georgianna; Kelly, Terri M.; Mazur, Paul; Pandit, Shilpa; Santoro, Joseph; Sitlani, Ayesha; Wang, Chuanlin; Williamson, Joanne; Miller, Douglas K.; Thompson, Chris M.; Zaller, Dennis M.; Forrest, Michael J.; Carballo-Jane, Ester; Luell, Silvi

CS Departments of Medicinal Chemistry, Metabolic Disorders Immunonology and Pharmacology, Merck Research Laboratories, Rahway, NJ, 07065, USA

SO Journal of Medicinal Chemistry (2004), 47(10), 2441-2452
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

OS CASREACT 141:7063

GI



I

AB A novel series of selective ligands for the human glucocorticoid receptor (hGR) are described. Preliminary structure-activity relationships were focused on substitution at C-1 and indicated a preference for 3-, 4-, and 5-substituted aromatic and benzylic groups. The resulting analogs, e.g., I [R = OH, R1 = 3,4,5-MeO(F2)C6H2, CH2C6H4F-4], exhibited excellent affinity for hGR (IC50 1.9 nM and 2.8 nM, resp.) and an interesting partial agonist profile in functional assays of transactivation (tyrosine aminotransferase, TAT, and glutamine synthetase, GS) and transrepression (IL-6). The most potent compds. were I [R = 4-FC6H4, 2-thienyl, R1 = OH]. These candidates showed highly efficacious IL-6 inhibition vs. dexamethasone. I [R = 2-thienyl, R1 = OH] was evaluated in vivo in the mouse LPS challenge model and showed an ED50 = 4.0 mg/kg, compared to 0.5 mg/kg for prednisolone in the same assay.

IT 614762-99-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and glucocorticoid receptor binding of [aryl(hydroxy)methyl]naphthopyrazoles)

RN 614762-99-1 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:836773 CAPLUS
DN 139:323524
TI Preparation of 1H-Benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
IN Ali, Amjad; Balkovec, James M.; Graham, Donald W.; Thompson, Christopher F.; Quraishi, Nazia
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 233 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003086294	A2	20031023	WO 2003-US10867	20030408
	WO 2003086294	A3	20040715		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2481320	A1	20031023	CA 2003-2481320	20030408
	AU 2003221706	A1	20031027	AU 2003-221706	20030408
	EP 1496892	A2	20050119	EP 2003-718285	20030408
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005528385	T	20050922	JP 2003-583321	20030408
	US 2005256315	A1	20051117	US 2005-508897	20050428
PRAI	US 2002-371948P	P	20020411		
	WO 2003-US10867	W	20030408		

OS MARPAT 139:323524
GI



I



II

AB Benzindazoles I [n = 0-2; J, K, L = (un)substituted CH2, NH; X = bond, CO, (un)substituted NH, NHCO, 1,1-cyclopropanediyl; R1, R2 = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, aryl, aralkyl, heterocyclic, aryloxy, aroyloxy, OH; R3 = H, (un)substituted OH, alkyl, aryl, aralkyl; Y = H, (un)substituted OH, SH, S(O)H, SO2H, CH2, NH2, SO2NH2, CO2H, NO2, acyl, CN, halogen; and the carbocyclic rings may be further substituted] were prepared for use as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions (no data). Thus, Wieland-Miescher ketone was ketalized, hydroxymethylenated, cyclized with 4-FC6H4NHNH2, deketalized, treated with Ph3P+CH2OMe Cl-, and subjected to Grignard reaction with 4-FC6H4MgCl to give the benzindazole II.

IT 614762-99-1P 614763-23-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1H-benzo[f]indazol-5-yl derivs. as selective glucocorticoid receptor modulators)

RN 614762-99-1 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614763-23-4 CAPLUS
CN Spiro[5H-benz[f]indazole-5,2'-oxirane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:590999 CAPLUS
DN 139:149523
TI Preparation of non-steroidal ligands for the glucocorticoid receptor
IN Scanlan, Thomas S.; Shah, Nilesh
PA The Regents of the University of California, USA
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003061651	A1	20030731	WO 2003-US1997	20030122
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2473886	A1	20030731	CA 2003-2473886	20030122
	US 2003176478	A1	20030918	US 2003-350260	20030122
	US 6831093	B2	20041214		
	EP 1467730	A1	20041020	EP 2003-710722	20030122
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005523254	T	20050804	JP 2003-561595	20030122
	US 2005054700	A1	20050310	US 2004-972250	20041022
PRAI	US 2002-351484P	P	20020122		
	US 2002-373757P	P	20020417		
	US 2003-350260	A3	20030122		
	WO 2003-US1997	W	20030122		

OS MARPAT 139:149523
GI



I



II

AB Naphthoheterocycles I [A, B, D = C, N, O, S, at least one of A, B, and D being N, O, or S; W = C, O, N, S; R1 = H, (un)substituted alkyl, acyl, NH2, CO2H, aralkyl, CONH2, heterocyclic, CN, halogen; R2, R3, R5, R6, R6', R7 = H, (un)substituted alkyl, acyl, alkoxy, NH2, sulfonyl, sulfinyl, SH, CO2H, aralkyl, CONH2, heterocyclic, OH, CN, halogen; R2', R3', R5', R7', R8 = absent or H, (un)substituted alkyl, acyl, NH2, alkoxy, sulfonyl, sulfinyl, SH, aralkyl, CONH2, heterocyclic, CN, halogen; R4 = absent or H, (un)substituted alkyl, acyl, NH2, CO2H, aralkyl, CONH2, heterocyclic, CN, halogen; R9 = absent or H, (un)substituted alkyl, alkoxy, NH2, CO2H, CN, halogen, O, S, OH; R10 = absent or H, (un)substituted alkyl, acyl, CO2H, aralkyl, aryl, cycloalkyl, heterocyclic; R2R10 = atoms required to form a ring; R11, R12 = H, (un)substituted alkyl, acyl, NH2, alkoxy, sulfonyl, sulfinyl, SH, aryl, aralkyl, CONH2, heterocyclic, OH, CN, halogen, O, S] were prepared as non-steroidal ligands for the glucocorticoid receptor. They are useful for treating or preventing diseases (e.g., obesity, diabetes, depression, neurodegeneration of an inflammatory disease) associated with glucocorticoid binding to the glucocorticoid receptor. Thus, Wieland-Miescher ketone was converted to its 5-ethyleneketal, hydroxymethylenated, and cyclized with 4-FC6H4NHNH2 to give the benzindazolone II which had IC50 of 436 nM in a glucocorticoid receptor binding test.

IT 571203-14-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of non-steroidal ligands for the glucocorticoid receptor)

RN 571203-14-0 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 18 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1991:185370 CAPLUS
DN 114:185370
TI Receptor-based design of novel dihydrofolate reductase inhibitors: benzimidazole and indole derivatives
AU Ohemeng, Kwasi A.; Roth, Barbara
CS Wellcome Res. Lab., Research Triangle Park, NC, 27709, USA
SO Journal of Medicinal Chemistry (1991), 34(4), 1383-94
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 114:185370
GI



I



II

AB 2,4-Diamino-6-benzylbenzimidazole I (X = N) and the corresponding indole I (X = CH), as well as more complex tri- and tetracyclic derivs. II [R = R1 = H; RR1 = S(CH2)2S (III)] were prepared as inhibitors of the enzyme dehydrofolate reductase (DHFR). These were designed on the basis of mol. modeling to the known x-ray structure of Escherichia coli DHFR, in an effort to determine whether one could drastically alter the diamino configuration by placing one amino substituent in a 5-membered nitrogen-containing ring and the second in the ortho position of a fused ring and still inhibit DHFR significantly. Although the electronics and bond angles are quite different from that of a 2,4-diaminopyrimidine, the pKa values are in an appropriate range, and hydrogen-bond distances appear to be quite reasonable. The most active compound, I (X = CH), was very unstable and active only in the 10-4 M range. Dihydroindenoimidazole derivs. such as III showed quite a good fit to the enzyme by modeling studies, but had low activity. Since the most active compound made was 2 orders of magnitude weaker as an inhibitor of bacterial DHFR than the unsubstituted 5-benzyl-2,4-diaminopyrimidine, such a ring system was unlikely to produce the high inhibitory potency of trimethoprim, even with greatly improved hydrophobic contacts. Thus the 2,4-diaminopyrimidine system remains unparalleled to date for the competitive inhibition of this enzyme.
IT 133100-33-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and attempted catalytic hydrogenation of)
RN 133100-33-1 CAPLUS
CN Spiro[1,3-dioxolane-2,5'(1'H)-indeno[5,6-d]imidazol]-2'-amine, 6',7'-dihydro-8'-nitro- (9CI) (CA INDEX NAME)



IT 133100-32-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and catalytic hydrogenation of)
RN 133100-32-0 CAPLUS
CN Spiro[1,3-dithiolane-2,5'(1'H)-indeno[5,6-d]imidazol]-2'-amine, 6',7'-dihydro-8'-nitro- (9CI) (CA INDEX NAME)



IT 133100-09-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and dihydrofolate reductase inhibitory activity of)
RN 133100-09-1 CAPLUS
CN Spiro[1,3-dithiolane-2,5'(1'H)-indeno[5,6-d]imidazole]-2',8'-diamine, 6',7'-dihydro- (9CI) (CA INDEX NAME)



L8 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1961:76309 CAPLUS
DN 55:76309
OREF 55:14517c-i,14518a-i,14519a-i,14520a-f
TI Steroidal [3,2-c]pyrazoles. II. Androstanes, 19-norandrostanes, and their unsaturated analogs
AU Clinton, R. O.; Manson, A. J.; Stonner, F. W.; Neumann, H. C.; Christiansen, R. G.; Clarke, R. L.; Ackerman, J. H.; Page, D. F.; Dean, J. W.; Dickinson, W. B.; Carabateas, Clarissa
CS Sterling-Winthrop Inst., Rensselaer, NY
SO Journal of the American Chemical Society (1961), 83, 1478-91
CODEN: JACSAT; ISSN: 0002-7863
DT Journal
LA Unavailable
OS CASREACT 55:76309
AB cf. CA 53, 16211b. Several types of steroidal [3,2-c]pyrazoles (I) were

prepared from 3-oxoandrostanes, 3-oxoandrost-4-enes, 3-oxoandrosta-4,6-dienes, 3-oxo-19-norandrostanes, and 3-oxo-19-norandrost-4-enes by formylation at the 2-position and reaction of the resulting 2-hydroxymethylene-3-oxo steroid (II) with N2H4 or substituted hydrazine. The I frequently possessed enhanced or unusual endocrinol. activities. These included greatly increased anabolic-androgenic ratios, or the unexpected development of estrogenic activity. The appropriate 3-oxo steroid (III) treated with NaH and HCO2Et in C6H6 by the method of Weisenborn, et al. (CA 49, 12482f), yielded the corresponding II; method A. NaH in C6H6 treated with stirring with 5-25 mol-% absolute MeOH and after 0.5 h. with the appropriate III gave the corresponding II; method B. The appropriate III formylated by the method of Johnson and Posvic (CA 41, 6537c) with dry NaOMe in C6H6 gave the corresponding II; method C. III (15 mmol) in 100 cc. dry C5H5N under N treated successively with 8.0 cc. HCO2Et and 0.66 g. Na in 6 cc. absolute MeOH, kept at room temperature overnight, poured into 75 cc. AcOH in 700 cc. H2O, and filtered, the residue extracted with C6H6 or CH2Cl2, the extract washed and extracted with 2% aqueous KOH, and the basic extract acidified with 10 cc. AcOH yielded the corresponding II, method D. A similar procedure using an equivalent amount of dry NaOEt instead of NaOMe-MeOH gave also II; method E. By these methods were prepared the 2-hydroxymethylene derivs. of the following III (III, method, reaction time in hrs., and % yield of II given): 17α-ethynylandrostan-17β-ol-3-one (IV), A or C, 48, 35-6 (D or E, 2 days, 81-3%, m. 170.8-7.5°); 17α-Et analog of IV, C, 24, 100; 17α-MeC.tplbond.C analog of IV, C, 72, 85; 17α-Pr analog of IV, A, 168, 98 (B, 72 h., 98%, m. about 80°); 4,4,17α-trimethyl analog of IV, D, 24, 77 (m. 150-4°); 6α,17α-di-Me analog of IV, C, 24, 100 [m. 190.8-9.8° (Me2CO), [α]D 54.3° (all rotations were measured in CHCl3 at 25° and 1% concentration)]; 19-norandrostan-17β-ol-3-one (V), D, 4, 100 (resin); 17α-Me derivative of V, C, 48, 100 [m. 206.2-10.6°, [α]D 96.1°]; 17α-Et derivative of V, E, 4, 60 (hydrate m. 72-115°); 17α-CH.tplbond.C derivative of androst-4-en-17β-ol-3-one (VI), E, 24, 50 (m. 182-8°); 17α-CH2:CH derivative of VI, A or B, 72, 88-94; 17α-Et derivative of VI, A, 72, 100 [isolated as the Na salt monohydrate, m. 200-30° (decomposition)]; 17α-CH2:CHCH2 derivative of VI.0.5H2O (m. 95.4-109.8°, [α]D 75.4°), D, 96, 83; 4,4-dimethylandrost-5-en-17β-ol-3-one, D, 72, 71 (m. 148-54°); 4,4-dimethyl-17β-methoxyandrost-5-en-3-one, E, 24, 85 [m. 138.8-9.6° (iso-PrOH), [α]D -44.1°]; 4,4,17α-trimethylandrost-5-en-3-one, D, 24, 83 [m. 164.2-6.0 (iso-PrOH), [α]D -59.2°]; androst-4-ene-11β,17β-diol-3-one, A, 96, 50 (m. 168-90°); 9β,11β-epoxy-17α-methylandrost-4-en-17β-ol-3-one, E, 24, 100 (m. 80-115°); androsta-4,6-dien-17β-ol-3-one, A, 96, 95; 17α-ethylandrosta-4,6-dien-17β-ol-3-one, A, 72, 98 (isolated as the H2O-soluble Na derivative). Androstan-17β-ol-3-one (VII) gave similarly by method A during 72 h., by method C during 72 h., and by method E overnight 92, 49, and 99%, resp., yield of the corresponding II. The 17α-Me derivative of VII gave by methods A, B, and C during 48 h. and by method E overnight 27, 90-5, 90-5, and 99%, resp., of the corresponding II. 17α-Methylandrost-4-en-17β-ol-3-one gave by method A during 120 h. 90% corresponding II, m. 178.6-9.8°, [α]D 14.0°. The appropriate II (0.01 mol) in 100 cc. EtOH refluxed 2-6 h. with 0.015-0.02 mol 85-100% N2H4.H2O gave the corresponding I. In this manner were prepared the following [3,2-c]pyrazoles [corrected m.p., and [α]D (CHCl3) given]: 17β-hydroxyandrostano(VIII) ethanolate, 127.6-8.4° (EtOH), resolidified and remelted at 217-25°, 55.1°; 17α-Me derivative (IX) of VIII.EtOH, 229.8-42.0° (EtOH) [solvate, prisms, m. about 148°, resolidified and remelted at 228-34°), 35.7° [48.6° (c 1, MeOH)]; N-Ac derivative of IX.EtOH (from IX

with Ac2O-C5H5N), 111.4-15.4° (EtOH), 43.1°; N-EtCO derivative of IX, 134.4-48.0° (EtOH), 45.1°; N-(p-ClC6H4OCH2CO) derivative of IX, 164.8-7.6° (Me2CO), 35.1°; 17α-CH.tplbond.C derivative of VIII, 237.4-42.0° (EtOH), 12.4°; 17α-Et derivative of VIII.H2O, 249.0-51.6° (EtOH), 32.7°; 17α-MeC.tplbond.C derivative of VIII, 143° (decomposed to a foam), -29.6° (c 1, C5H5N) [-29.3° (c 1, HCONMe2)]; 6α,17α-di-Me derivative of VIII, 156.0-74.0° (decomposition), 44.8°; 4,4,17α-tri-Me derivative of VIII, 269.2-74.6° (MeOH), 4.7° (c 1, EtOH) [5.9° (c 1, C5H5N)]; 4,4-di-Me derivative of VIII, 176.0-9.0° (MeOH), 30.0°; 17β-hydroxy-19-norandrostano- (X), 248.0-51.5° (EtOH), -; 17α-Et derivative of X, 149.2-50.4° (EtOH), 93.0° (c 1, C5H5N); 17β-hydroxyandrost-4-eno- (XI), 272.0-6.6° (EtOH), 147.6° (c 1, C5H5N); N,O-di-EtCO derivative (XII) of XI, 148.8-51.6° (Et2O-pentane), 52.4°; 17α-CH.tplbond.C derivative of XII, 239.6-6.2° (Me2CO), 29.0°; 17α-CH2:CH derivative of XII, 247.0-59.4° (EtOH), 101.2° [93.6° (c 1, dioxane)]; 17α-Et derivative of XII, 284.0-90.6° (EtOH), 102.1°; 17α-CH2:CHCH2 derivative of XII, 239.8-48.2° (aqueous EtOH), 93.7°; 4,4-dimethyl-17β-hydroxyandrost-5-eno-(XIII), 231.0-3.6° (aqueous EtOH), -20.1°; 17β-MeO analog of XIII, 236.4-9.2° (iso-PrOH), -34.2°; 17α-Me derivative of XIII, 270.4-6.0° (MeOH), -55.0° (c 1, EtOH); 11β-OH derivative (XIV) of XI.EtOH, 233.2-46.0° (EtOH), 167.5° (c 1, C5H5N); N,O-di-EtCO derivative of XIV, 107.6-12.6° (MeOH), 80.7°; 9β,11β-epoxy-17β-hydroxy-17α-methylandrost-4-eno-, 233.2-46.8° (Me2CO), -145.0°; 17β-hydroxyandrosta-4,6-dieno-, 272.8-7.0° (EtOH-EtOAc), -137.2° (c 1, EtOH); 17α-ethyl-17β-hydroxyandrosta-4,6-dieno-, 305-15° (EtOH), -55.4° (c 1, C5H5N). 2-Hydroxymethyleneandrostan-17β-ol-3-one (XIVa) (5.00 g.), 3.80 g. N2H4.H2SO4, and 400 cc. EtCO2H heated 5 days at 70°, poured into H2O, and extracted with Et2O gave 1.82 g. 17β-propionyloxyandrostano[3.2-c]pyrazole (XV), m. 181.2-95.2° (Et2O), [α]D 40.2°. VIII.EtOH (1.80 g.), 1.43 g. p-MeC6H4SO3H, 10 cc. EtCO2H, and 25 cc. (EtCO)2O kept 24 h. at room temperature and poured into 400 cc. H2O gave 2.25 g. N-EtCO derivative of XV, needles, m. 180.0-1.8° (hexane-Et2O), [α]D 47.2°. VIII (5.00 g.) in 80 cc. C5H5N kept 20 h. at room temperature with 15.0 g. 3-cyclohexylpropionic anhydride, heated 0.5 h. on the steam bath, and worked up gave 1.12 g. N-cyclohexylpropionyl derivative (XVI) of 17β-cyclohexylpropionyloxyandrostano[3,2-c]pyrazole (XVII), needles, m. 117.8-20.8° (Et2O-MeOH), [α]D 41.4°. XVI (3.4 g.) and 40 cc. 80% AcOH refluxed 2 h. gave 1.53 g. XVII, needles, m. 236.4-8.6° (Me2CO-MeOH), [α]D 41.9°. IX (7.00 g.) in 100 cc. Ac2O refluxed 1.5 h. yielded 7.68 g. N-Ac derivative (XVIII) of 17β-acetoxy-17α-methylandrostano[3,2-c]pyrazole (XIX), needles, m. 144.4-5.8°, [α]D 55.0°. XVIII (5.73 g.) in 60 cc. 80% AcOH refluxed 1.5 h. gave 2.17 g. XIX, needles m. 224.8-6.8° (MeOH), [α]D 44.3°. MeNHNH2.H2SO4 (1.52 g.) and 1.97 g. NaOAc in 80 cc. H2O added to 3.00 g. XIVa in 400 cc. EtOH and refluxed 0.5 h. yielded 2.20 g. 17β-hydroxy-17α-methylandrostano[3,2-c]-1'-methylpyrazole (XX), m. 249.6-59.0° (MeOH), [α]D 39.0° (c 1, EtOH). XIVa (8.5 g.) and 2.3 g. 2-methylsemicarbazide in the min. amount boiling BuOH refluxed 18 h. gave 4.8 g. N-methylsemicarbazone, powder, m. 140° (decomposition); a 2.7 g. portion heated 6 h. at 205° under N gave 0.78 g. 2'-Me isomer (XXI) of XX, m. 186.6-98.0° (Me2CO), [α]D 38.3° (c 1, EtOH). XX (1.85 g.), 10 cc. MeOH, and 10 cc. MeI kept 60 h. at room temperature in a sealed tube, heated 1 h. at 100°, and evaporated gave a mixture of white prisms and yellow spherulites; the mixture triturated with a a few cc. CH2Cl2 left 1.43 g. 17β-hydroxy-17α-methylandrostano[3,2-c]-1',2'-dimethylpyrazolium iodide, m. 282.4-91.2° (decomposition) (MeOH-MeCN), [α]D 35.8° (c 1, MeOH). XIVa (3.33 g.), 1.10 g. PhNHNH2, and

100 cc. MeOH refluxed 1.5 h. gave 3.29 g. 2'-Ph analog of XXI.MeOH, needles, decompose 99.4° to a foam, [α]D 55.0°. 17α-Ethynylandrostane-3β,17β-diol (5.1 g.) in 125 cc. C5H5N treated with 5.0 g. CrO3 gave 2.05 g. 17α-ethynylandrostan-17β-ol-3-one, m. 287.4-9.4° (EtOH), [α]D -25.4° (c 1, C5H5N). 17α-Vinylandrostane-3β,17β-diol (3.18 g.) in 20 cc. dry C5H5N treated with 1.33 g. CrO3 gave 2.50 g. 17α-vinylandrostan-17β-ol-3-one (XXII), needles, m. 183.0-3.6° (EtOAc), [α]D 8.8°. XXII formylated by method C during 3 days gave 36-7% 2-HOCH2 derivative (XXIII) of XXII, m. 132-7°. Method C at 45-50° during 2 days and method D during 2-48 h. yielded 47-53 and 4-15%, resp., of XXIII. Crude XXIII condensed with N2H4.H2O yielded the 17α-CH2:CH derivative of VIII, prisms, m. above 300° (MeOH), [α]D 24.5°. Androstan-3β-ol-17-one (46.3 g.) in 400 cc. dry Et2O kept 3 days at room temperature with 0.9 g. p-MeC6H4SO3H.H2O yielded 38.0 g. epimeric mixture of 3-tetrahydropyranyl ethers (XXIV), m. 160-95°. MeC.tplbond.CH (30 g.) added with stirring during 1 h. under dry ice-cooled reflux to 0.3 EtMgBr in 100 cc. Et2O and 250 cc. THF (THF), the mixture treated slowly dropwise with 33.5 g. XXIV in 250 cc. dry THF, refluxed overnight, treated with 50 cc. saturated aqueous NH4Cl, and worked up, and the crude product dissolved in 300 cc. EtOH, treated with 5 cc. 85% H3PO4, kept 2 days at room temperature, and diluted with H2O gave 22.6 g. 17α-propynylandrostane-3β,17β-diol, m. above 150°, which oxidized with 18.0 g. CrO3 and 300 cc. C5H5N gave 66% 17α-propynylandrostan-17β-ol-3-one, prisms, m. 192.8-7.0° (MeOH), [α]D -18.7°, -28.2° (c 1, C5H5N). 17α-Allylandrost-5-ene-3β,17β-diol in EtOH hydrogenated over 22% Pd-SrCO3 gave 17α-propylandrostane-3β,17β-diol, needles, m. 188.6-91.0° (EtOAc), [α]D -5.3°, which oxidized with CrO3-C5H5N gave 17α-propylandrostan-17β-ol-3-one, prisms, m. 131.8-2.4° (EtOAc), [α]D 15.5°. 6α,17α-Dimethylandrost-4-en-17β-ol-3-one (10 g.) in 150 cc. dry Et2O and 150 cc. dry THF stirred 50 min. with 2.5 g. Li and worked up, and the crude product (9.87 g.) oxidized in 100 cc. C5H5N with 10.0 g. CrO3 yielded 6α, 17α-dimethylandrostan-17β-ol-3-one, prisms, m. 181.6-4.6° (EtOAc), [α]D 10.3°. 2-Hydroxymethylene-7α-methyl-19-norandrostan-17β-ol-3-one condensed in the usual manner with N2H4.H2O gave 17β-hydroxy-17α-methyl-19-norandrostano[3,2-c]pyrazole-EtOH, m. 146-56° (EtOH); it gave also an Me2CO solvate, m. 148° (decomposition), and an EtOAc solvate, m. 125-6° (decomposition), which heated 48 h. in vacuo at 110° gave the solvent-free material, m. 140.4-52.4°, [α]D 90.0°. XII (2.33 g.) in 50 cc. 80% AcOH refluxed 1.5 h. gave 17β-propionyloxyandrost-4-eno[3,2-c]pyrazole, m. 166.6-72.0° (Me2CO-hexane), [α]D 99.5°. XI (5.0 g.) in 200 cc. MeOH treated with 0.016 mol HCl in 15 cc. Et2O and then 40 cc. H2O, followed by 1.3 g. KOCN in 10 cc. H2O, and filtered yielded 4.2 g. N-carbamoyl derivative (XXV), m. 227-8°, [α]D 83.4° (c 1, C5H5N), of XI. XXV (8.0 g.) in 500 cc. AcOH treated dropwise at about 14° during 10 min. with 3.2 g. CrO3 in 8 cc. H2O and 24 cc. glacial AcOH, stirred 2 h. at 14°, and 3 h. at room temperature, and worked up gave 4.8 g. N-carbamoyl derivative (XXVI) of 17-oxoandrost-4-eno[3,2-c]pyrazole (XXVII), needles, m. 273-4° (CHCl3), [α]D 136.3°, 142.2° (c 0.25, C5H5N). XXVI (4.57 g.), 1800 cc. EtOH, and 10 cc. concentrated HCl refluxed 6 h., concentrated to 900 cc., diluted with 600 cc. H2O and 20 cc. concentrated NH4OH, concentrated, and filtered gave 3.95 g. of product, prisms, m. 258.6-63.8°, [α]D 209.4°, 211.8° (c 1, C5H5N), 199.1° (c 1, EtOH). 2-Hydroxymethylene-17α-methylandrost-4-en-17β-ol-3-one (XXVIII) with N2H4.H2O gave 17β-hydroxy-17α-methylandrost-4-eno[3,2-c]pyrazole (XXIX), plates, m. 250.0-8.0° (EtOH), [α]D 103.5° (c 1, MeOH),

133.2° (c 1, C5H5N). XXIX with Ac2O-C5H5N during 48 h. at room temperature yielded the N-Ac derivative of XXIX, m. 92.0-100.2° (EtOH), [α]D 67.1°, 87° (c 1, C5H5N). XXVIII with MeNHNH2 in aqueous EtOH gave 44% 1-Me derivative (XXX) of XXIX, prisms, m. 175.2-93.2° (MeCN), [α]D 103.6°, 132.9° (c 1, C5H5N). XXX (5.25 g.), 10 cc. MeOH, and 15 cc. MeI heated 2.5 h. at 100° in a sealed tube gave 2.05 g. 17β-hydroxy-17α-methylandrost-4-eno[3,2-c]1',2'-dimethylpyrazolium iodide, pale yellow, m. 257.8-61.6° (decomposition)(EtOH), [α]D 13.3° (c 1, MeOH). 17α-Propargylandrost-4-en-17β-ol-3-one, m. 135.8-43.2°, [α]D 65.2°, formylated by method B during 6 days, and the crude 2-hydroxymethylene derivative (84%) condensed with N2H4.H2O gave 17α-HC.tplbond.CCH2 analog of XXIX, prisms, m. 130.4-40.6° (aqueous EtOH), [α]D 75.4°. 17α-Propylandrost-5-ene-3β,17β-diol, m. 188.0-92.8°, [α]D -59.2°, subjected to an Oppenauer oxidation gave 17α-propylandrost-4-en-17β-ol-3-one (XXXI), plates, m. 114.6-16.0° (C6H6-hexane), [α]D 75.4°. XXXI formylated by method A during 3 days, and the resulting crystalline 2-hydroxymethylene derivative condensed in the usual manner with N2H4.H2O gave a small amount of 17-methyl-17-propylandrosta-4,12(13)-dieno[3,2-c]pyrazole, needles, m. 203.0-12.0°, and mainly 17α-Pr analog of XXIX, plates, m. 223.0-32.4° (aqueous EtOH), [α]D 89.5°. 6α,17α-Dimethylandrost-4-en-17β-ol-3-one formylated by method A during 5 days, and the resulting 2-HOCH2 derivative (85%), m. 145-65°, condensed with N2H4.H2O yielded 6α,17α-dimethyl-17β-hydroxyandrost-4-eno[3,2-c]pyrazole, needles, m. 170.0-8.6° (decomposition) (EtOAc). 6α-Methyl-17α-propynylandrost-4-en-17β-ol-3-one formylated by method D during 2 days, and the crude product (100%), m. 108-30°, condensed with N2H4.H2O yielded 17β-hydroxy-6α-methyl-17α-propynylandrost-4-eno[3,2-c]pyrazole, m. 166.2-70.6° (MeOH), [α]D 7.6°. The mother liquors from the preparation of 4,4-dimethylandrost-5-en-17β-ol-3-one chromatographed on Al2O3 gave 4,4-dimethyl-17β-methoxyandrost-5-en-3-one, needles, m. 134.4-8.2° (MeOH), [α]D -15.0°. 9α-Fluoro-17α-methylandrost-4-ene-11β,17β-diol-3-one formylated by method E during 6 days, and the resulting glassy, resinous 2-HOCH2 derivative condensed with N2H4.H2O gave 11β,17β-dihydroxy-9α-fluoro-17α-methylandrost-4-eno[3,2-c]pyrazole, m. 281° (decomposition) (Me2CO-EtOAc), [α]D 101.3° (c 1, EtOH). 9α-Fluoro-17α-methylandrost-4-en-17β-ol-3,11-dione formylated with HCO2Et by method B during 5 days, and the resulting crude 2-HOCH2 derivative condensed with N2H4.H2O yielded 9α-fluoro-17β-hydroxy-11-oxo-17α-methylandrost-4-eno[3,2-c]pyrazole, m. 292-300° (decomposition), [α]D 119.6° (c 0.15, EtOH). 2-Hydroxymethylene-17α-methyl-19-norandrost-4-en-17β-ol-3-one condensed with N2H4.H2O gave 17β-hydroxy-17α-methyl-19-norandrost-4-eno[3,2-c]pyrazole-0.5EtOH (XXXII.0.5EtOH), needles m. 111.0-26.1° (decomposition) (EtOH), [α]D 0.2°, which with excess (EtCO)2O during 48 h. at room temperature gave the N-EtCO derivative, m. 131.8-4.2°, [α]D -6.4°. 17α-Ethyl-19-norandrost-4-en-17β-ol-3-one formylated by method B during 4 days, and the resulting crude 2-HOCH2 derivative (85%), m. 87-100°, condensed with N2H4.H2O gave 17α-Et analog of XXXII, m. from 147° with gradual decomposition (MeCOEt), [α]D 59.1° (c 1, C5H5N). 17α-Methylandrosta-4,6-dien-17β-ol-3-one gave by method C during 3 days 100% crude 2-HOCH2 derivative, m. from 87° with gradual decomposition, which condensed with N2H4.H2O gave 52% 17β-hydroxy-17α-methylandrosta-4,6-dieno[3,2-c]pyrazole (XXXIII), yellow plates, m. 279.2-84.0° (EtOAc), [α]D -126.1° (c 1, C5H5N); N-Ac derivative of XXXIII, m. 151.8-4.8° (Et2O-pentane), [α]D -244°, -192° (c 1, C5H5N). 17α-Ethyltestosterone brominated with N-bromosuccinimide and the resulting 6-Br derivative dehydrobrominated with collidine gave 17α -ethylandrosta-4,6-dien-17β-ol-3-one, yellow needles, m.

177.4-82.2° (EtOH), [α]D 73.1° (c 1, C5H5N).

IT 112716-45-7P, 9β-Androst-4-eno[3,2-c]pyrazol-17β-ol, 9,11β-epoxy-17-methyl-
RL: PREP (Preparation)
(preparation of)

RN 112716-45-7 CAPLUS

CN 2H-Cyclopent[7,8]oxireno[4b,5]phenanthro[2,3-c]pyrazol-7β-ol, 4,4a,5aα,6,6a,7,8,9,9aα,9bβ,10,11-dodecahydro-4aβ,6aβ,7α-trimethyl- (6CI) (CA INDEX NAME)

Absolute stereochemistry.